5 Firms Guide $834M Chinese Biopharma SPAC Merger

Beijing-based biopharmaceutical company Yisheng Biopharma Co. Ltd., announced on Thursday that it will merge with Hong Kong-based blank-check company Summit Healthcare Acquisition Corp. in a transaction that values the new company at $834 million.

Related Keywords

Beijing ,China ,Renee Hickman ,Yisheng Biopharma Co ,Summit Healthcare Acquisition Corp ,Yisheng Biopharma ,Hong Kong Based ,Summit Healthcare Acquisition ,